Cingulate Inc. CING
4.53 USD -0.19 (-4.03%)
Nov 4, 2026, 12:39 PM EST
4.51 Day range 4.85
3.16 52-week range 11.89
- YTD
- +4.38%
- 1 year
- +22.43%
- Market cap
- 65.87M
- EPS (ttm)
- -3.51
- Shares out
- 3.21M
- Forward P/E
- -0.65
- YTD return
- +4.38%
- 1-year return
- +22.43%
- Volume
- 67.94K
- Avg volume
- 120.55K
- Open
- 4.75
- Previous close
- 4.72
- Day's range
- 4.51 – 4.85
- 52-week range
- 3.16 – 11.89
- Price target
- 48.33 (+967.0%)
- Earnings date
- Aug 13, 2024
5D -0.21 (-4.01%)
Key statistics
- Enterprise value
- -2.56M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.70
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -10.79M
- Total cash
- 10.04M
- Total debt
- 234.17K
- Return on equity
- -273.82%
- Short % of float
- 4.61%
- 50-day average
- 4.27
- 200-day average
- 7.16
Analyst view
Price target (mean) 48.33 +967.0% upside
Now 4.53
- Target (low)
- 8.00
- Target (mean)
- 48.33
- Target (high)
- 75.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -1.49.
Financials — quick view
CING Revenue — quarterly 0
CING Net income — quarterly -5.87M
CING EPS — quarterly -0.95
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -2.22 | -1.83 | +0.39 | +17.57% |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -5.47 | — | — |
| May 8, 2024 | Mar 1, 2024 | -26.41 | -7.20 | +19.21 | +72.74% |
| May 8, 2024 | Mar 1, 2024 | -26.41 | — | — | — |
| Apr 5, 2024 | Dec 1, 2023 | -2.60 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Maxim Group | up | Hold | Buy |
| Jan 5, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 22, 2023 | Laidlaw & Co. | down | Buy | Hold |
| Dec 19, 2023 | Maxim Group | down | Buy | Hold |
| Dec 18, 2023 | Maxim Group | down | Buy | Hold |
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cingulate.com
News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma 
Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9 
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $44 
Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate 
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness 
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile 
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology 
Cingulate Joins Russell 3000E Index 
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
Your note
Sign in to keep a note on CING — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CALLAHAN JENNIFER L. | Officer | Purchase | Sep 14, 2023 | 45,508 |
| MYERS LAURIE | Chief Operating Officer | Sale | Aug 14, 2024 | 0 |
| WERTH PETER J. | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 10, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Jane Street Group, LLC | 0.65% | 21,031 | 100.11K | Sep 29, 2024 |
| UBS Group AG | 0.43% | 13,749 | 65.44K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.35% | 11,276 | 53.67K | Sep 29, 2024 |
| Bank of America Corporation | 0.06% | 1,878 | 8.94K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.05% | 1,572 | 7.48K | Sep 29, 2024 |
| FMR, LLC | 0.01% | 352 | 1.68K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.14% | 4,541 | 21.61K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.05% | 1,755 | 8.35K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 1,302 | 6.20K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.02% | 530 | 2.52K | Sep 29, 2024 |